Editor's Pick

In the next round of the eMERGE program, NIH is supporting development of methodologies for integrating genotypic and phenotypic risk scoring into clinical care. 

The company hopes to improve its Dragen analysis platform with data compression technology from Enancio and data management capabilities from BlueBee.

The firm launched a CE-IVD marked test for extremely drug-resistant TB and expects to incorporate the multiplexing technology in other assays.

Bruker's system has seen strong uptake among proteomics researchers, but its ability to generate large amounts of complex data has led to analysis challenges.

Users will be able to sequence over 20,000 samples simultaneously with the updated panel, which the firm expects to offer sometime in the third quarter for research use only. 

A handful of researchers and companies are hoping to finally bring the paper-based molecular diagnostic space to fruition.

The new pore, a complex between E. coli CsgG and part of CsgF, called certain homopolymers more accurately than an engineered version of CsgG.

In one study, the UK-based firm found that its RaDaR assay detected circulating tumor DNA in lung cancer patients up to a year before standard clinical progression occurred in most of the cases. 

The firm's SmartChip platform consists of a high-throughput liquid dispenser and a PCR instrument and can provide more than 5,000 reactions in one run.